Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Kenneth H. Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4774-2672; OpenAlex author ID A5009446517, A5075008829, A5130614649; NIH RePORTER profile ID 9242267. Sources: ClinicalTrials.gov.

Their work

Papers
70 (first author 5, last author 8)
Trials
3 (principal investigator on 3)
Grants
4
Labs led
1
Collaborators
214
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper, 1 grant · 2014: 3 papers, 1 trial · 2015: 4 papers · 2016: 1 paper, 1 trial · 2017: 5 papers · 2018: 13 papers · 2019: 7 papers, 1 trial, 1 grant · 2020: 4 papers, 1 grant · 2021: 7 papers, 1 grant · 2022: 5 papers · 2023: 1 paper · 2024: 4 papers · 2025: 6 papers · 2026: 7 papers

Papers 50 of 70

  1. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2026.2988↗
  2. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  3. A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-3189↗
  4. Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report. Last author DOI 10.21037/jgo-2025-aw-818↗
  5. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  6. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  7. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  8. Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy. Co-author DOI 10.1001/jamaoncol.2025.0460↗
  9. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Co-author DOI 10.1038/s41591-024-03362-3↗
  10. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  11. Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf139↗
  12. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  13. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  14. Advances in Systemic Therapy in Pancreatic Cancer. Co-author DOI 10.1016/j.hoc.2024.03.002↗
  15. Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication. Co-author DOI 10.1016/j.pan.2024.05.515↗
  16. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease. Co-author DOI 10.1093/jnci/djae095↗
  17. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery. Co-author DOI 10.3390/jcm13092631↗
  18. Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.5714↗
  19. Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.34269↗
  20. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26735↗
  21. Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s40291-022-00614-1↗
  22. Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system. Co-author DOI 10.1016/j.phro.2022.10.003↗
  23. ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer. Last author DOI 10.3390/cancers14122906↗
  24. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2021.0057↗
  25. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.4415↗
  26. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Co-author DOI 10.1097/sla.0000000000005080↗
  27. Predicting Gemcitabine Delivery by 18F-FAC PET in Murine Models of Pancreatic Cancer. Co-author DOI 10.2967/jnumed.120.246926↗
  28. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. Co-author DOI 10.3389/fonc.2021.678070↗
  29. Conformation-Specific Inhibitory Anti-MMP-7 Monoclonal Antibody Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Chemotherapeutic Cell Kill. Co-author DOI 10.3390/cancers13071679↗
  30. Longitudinal Monitoring of Simulated Interstitial Fluid Pressure for Pancreatic Ductal Adenocarcinoma Patients Treated with Stereotactic Body Radiotherapy. Co-author DOI 10.3390/cancers13174319↗
  31. Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes. Last author DOI 10.1002/cam4.3477↗
  32. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.33038↗
  33. Detection of incipient pancreatic cancer with novel tumor-specific antibodies in mouse models Co-author DOI 10.1101/2020.09.10.292193↗
  34. Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0231745↗
  35. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1002/cam4.2425↗
  36. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. Co-author DOI 10.1016/j.ctrv.2019.03.003↗
  37. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Co-author DOI 10.1126/science.aaw3145↗
  38. Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter? Co-author DOI 10.1158/1078-0432.ccr-18-3042↗
  39. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1398↗
  40. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Co-author DOI 10.1158/2159-8290.cd-19-0094↗
  41. Use of Machine-Learning Algorithms in Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse. Co-author DOI 10.3390/cancers11050606↗
  42. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adeno… Co-author DOI 10.1002/cncr.31218↗
  43. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase… Co-author DOI 10.1007/s10637-018-0580-2↗
  44. Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. Co-author DOI 10.1016/j.clcc.2017.12.001↗
  45. Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.clcc.2018.01.008↗
  46. Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence? Co-author DOI 10.1016/j.clcc.2018.01.009↗
  47. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Co-author DOI 10.1158/1078-0432.ccr-17-3099↗
  48. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  49. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. Last author DOI 10.1186/s12885-018-4605-1↗
  50. Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges. Last author DOI 10.3390/cancers10030067↗

Trials 3

  1. A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer Principal investigator NCT04137536↗
  2. Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma Principal investigator NCT02921022↗
  3. Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection Principal investigator NCT02241187↗

Grants 4

  1. Protein and proteolytic activity biomarkers of early stage pancreatic cancer R01CA208401↗
  2. Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer R01CA202762↗
  3. Imaging drug uptake and distribution in chemoradiation therapy of pancreatic cancer R01CA194321↗
  4. Biomarkers of exposure and response to environmental tobacco smoke in the pancrea K08ES019615↗

Closest collaborators

The 25 strongest of 214 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 44 shared papers, 2011–2026 · strength 5.11
  2. Anna M. Varghese · 24 shared papers, 2016–2026 · strength 3.24
  3. Wungki Park · 18 shared papers, 2019–2026 · strength 2.85
  4. Marinela Capanu · 14 shared papers, 2017–2026 · strength 1.83
  5. Fiyinfolu O. Balogun · 8 shared papers, 2024–2026 · strength 1.56
  6. Alice Chia-Chi Wei · 9 shared papers, 2021–2026 · strength 1.51
  7. Marsha Reyngold · 9 shared papers, 2017–2026 · strength 1.32
  8. David Arthur Tuveson · 10 shared papers, 2015–2026 · strength 1.21
  9. Maeve Aine Lowery · 15 shared papers, 1 shared grant, 2011–2019 · strength 1.19
  10. Christopher H. Crane · 8 shared papers, 2017–2026 · strength 1.18
  11. Vinod P. Balachandran · 8 shared papers, 2017–2026 · strength 1.13
  12. William R. Jarnagin · 8 shared papers, 2017–2026 · strength 1.10
  13. Danny N. Khalil · 6 shared papers, 2021–2026 · strength 1.02
  14. Kevin C. Soares · 6 shared papers, 2021–2026 · strength 0.99
  15. David Paul Kelsen · 11 shared papers, 2011–2025 · strength 0.98
  16. Olca Baştürk · 7 shared papers, 2015–2026 · strength 0.96
  17. Fergus Keane · 5 shared papers, 2024–2026 · strength 0.89
  18. Jeffrey A. Drebin · 6 shared papers, 2020–2026 · strength 0.88
  19. Christine A. Iacobuzio–Donahue · 8 shared papers, 2015–2026 · strength 0.87
  20. Carla Hajj · 5 shared papers, 2017–2026 · strength 0.76
  21. Michael Ian D'Angelica · 5 shared papers, 2020–2026 · strength 0.71
  22. Abraham Jing-Ching Wu · 5 shared papers, 2017–2025 · strength 0.68
  23. Paul Tempst · 1 shared paper, 1 shared grant, 2018–2021 · strength 0.68
  24. Paul C. Cockrum · 4 shared papers, 2020–2023 · strength 0.63
  25. Mark Andrew Schattner · 4 shared papers, 2017–2026 · strength 0.61

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.